checkAd

     487  0 Kommentare XBiotech to Present Positive Preliminary Survival Data on Xilonix(TM) at the 18th European Society of Medical Oncology's World Congress on Gastrointestinal Cancer - Seite 3 

    Contacts:
XBiotech
Meg Lewis
mlewis@xbiotech.com
+1 512.386.2983

Media liaison U.S.
Mariann Caprino
+1 917.242.1087

Media liaison ex-U.S.
Jonathan Kearney
+44 20 8618 2755; Mobile: +44 7725 925 841


    This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: XBiotech, Inc via Globenewswire

    Lesen Sie auch

    HUG#2015013

    GlobeNewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren
    Seite 3 von 3

    Verfasst von GlobeNewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    XBiotech to Present Positive Preliminary Survival Data on Xilonix(TM) at the 18th European Society of Medical Oncology's World Congress on Gastrointestinal Cancer - Seite 3 First Time Pivotal Phase III Xilonix Data to be Unveiled at Major Scientific Congress, Including Positive Preliminary Overall Mean Survival Data for Responders Developed Specifically to Treat Advanced Cancer, Xilonix is First Antibody Therapy to …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer